Monday, May 20, 2024
UMSOM’s Kahlert Institute for Addiction Medicine Hosts Inaugural Research Symposium
The University of Maryland School of Medicine (UMSOM) hosted the Kahlert Institute for Addiction Medicine’s Inaugural Research Symposium on Monday, May 6 at the school’s Baltimore campus.
Friday, May 17, 2024
Gov. Moore Signs Significant Funding Bills Securing the Future of Trauma Care for Marylanders
Dozens of Shock Trauma team members, trauma survivors, and supporters traveled to the state capital yesterday to support Maryland Governor Wes Moore, Senate President Bill Ferguson, and House Speaker Adrienne Jones as they signed a consequential bill into law expanding annual funding for Maryland’s renowned statewide trauma system. It will ensure access to world-class trauma care for Marylanders well into to the future.
Wednesday, May 01, 2024
UMSOM Preclinical Study Finds Novel Stem Cell Therapy Boosts Neural Repair After Cardiac Arrest
Researchers at the University of Maryland School of Medicine (UMSOM) have identified an innovation in stem cell therapy to regenerate neural cells in the brain after cardiac arrest in an animal model. The study led by Xiaofeng Jia, BM, MS, PhD, FCCM, Professor of Neurosurgery, found that the application of modified sugar molecules on human neural stem cells improved the likelihood of the therapy's success.
Tuesday, April 30, 2024
Miriam K. Laufer Appointed Interim Director of the Center for Vaccine Development and Global Health
University of Maryland School of Medicine (UMSOM) Dean, Mark T. Gladwin, MD, announced that Miriam K. Laufer, MD, Professor of Pediatrics, Medicine, and Epidemiology & Public Health, has been appointed as the Interim Head of UMSOM's Center for Vaccine Development and Global Health (CVD).
Tuesday, April 16, 2024
University of Maryland Greenebaum Comprehensive Cancer Center and AstraZeneca Partner to Enhance Community-Based Lung Cancer Screening and Detection for Marylanders at High Risk
With only a small percentage of Marylanders at high risk for lung cancer getting the recommended annual screening, the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) today launched a new statewide effort to increase annual screenings.
Wednesday, April 10, 2024
UMSOM Researchers Identify Safety of a Potential New Treatment to Manage Complications from Sickle Cell Disease
A drug approved to treat pulmonary arterial hypertension may be effective at managing hypertension and end-organ damage in patients with sickle cell disease, according to a new study published in Lancet Haematology. An early phase randomized clinical trial involving 130 patients with sickle cell disease found that the drug, called riociguat, was found to be safe to use and well tolerated in these patients and significantly improved their blood pressure. Preliminary efficacy data suggested the medication might improve heart function.
Friday, April 05, 2024
Researchers Identify New Genetic Risk Factors for Persistent HPV Infections
Human papillomavirus (HPV) is the second most common cancer-causing virus, accounting for 690,000 cervical and other cancers each year worldwide. While the immune system usually clears HPV infections, those that persist can lead to cancer, and a new finding suggests that certain women may have a genetic susceptibility for persistent or frequent HPV infections. These genetic variants, identified in a study led by University of Maryland School of Medicine researchers, could raise a woman’s risk of getting cervical cancer from a high-risk HPV infection.
Monday, April 01, 2024
UM School of Medicine Celebrates 2024 Medical Residency Match Day
After years of hard work and steadfast perseverance, University of Maryland School of Medicine (UMSOM) medical students gathered at the M&T Bank Exchange at the France-Merrick Performing Arts Center in Baltimore, Maryland on Match Day, March 15, 2024, to recognize their 2024 residency matches with a celebratory reception. Each year on Match Day, graduating medical students from around the country and at UMSOM discover where they will begin their careers as physicians.
Thursday, March 28, 2024
NIH selects Dr. Kathleen Neuzil as Director of The Fogarty International Center
Kathleen M. Neuzil, MD, MPH, Director of the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health, has been named the 13th director of the Fogarty International Center (FIC), which is part of the National Institutes of Health (NIH). Dr. Neuzil will be the first woman to hold the permanent directorship since the center’s founding in 1968 and will also hold the position of Associate Director for International Research at NIH.
Wednesday, March 20, 2024
New Study Reveals Insights into Lack of Durability in COVID Antibody Response to Infections & Vaccines
Researchers at the Institute of Human Virology (IHV) at the University of Maryland School of Medicine published a new study in the Journal of Infectious Diseases investigating the short-lived antibody response following SARS-CoV-2, the virus that causes COVID.